Pursuant to the Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and on receipt of approval of shareholders, Kilitch Drugs (India) has informed that the Company has fixed Tuesday, 24th March, 2026 as the Record Date in order to determine the number of shareholders entitled for Bonus Equity shares in the ratio of 1:1 (i.e. One bonus equity share of Rs. 10/- each for every one equity share of Rs. 10/- each held by the shareholders). Further, in accordance with SEBI circular dated 16th September, 2024, the deemed date of allotment of Bonus Equity Shares shall be Wednesday, 25th March, 2026. The shareholders whose names stand registered on the Company’s register of Members in respect of physical shares and on the Register of beneficial owners maintained by Depositories in respect of the shares held in electronic form as of closing hours of Tuesday, 24th March, 2026 shall be entitled to receive the bonus equity shares.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: